Lexaria Bioscience Corp. (NASDAQ: LEXX) Patented Technology Increasing Effectiveness And Potentially Lowering Healthcare Costs
(MENAFN- Investor Brand Network)
Company's patented DehydraTECH(TM) technology is showing the potential of reducing healthcare costs by improving oral medication administration – using capsule and pill form over injection administration
Lexaria's offering could potentially offer accelerated regulatory filing with the FDA and other regulators around the world
The company sub-licenses its DehydraTECH Technology for the delivery of fat-soluble active molecules and drugs while also operating four subsidiary companies
Lexaria Bioscience (NASDAQ: LEXX) , a global innovator in drug-delivery platforms, recently announced results from an anti-viral drug molecular characterization study performed by the National Research Council (“NRC”). Results confirmed that the drugs tested remained stable and did not undergo changes in chemical structure when processed with Lexaria's patented DehydraTECH(TM) technology. The use of DehydraTECH could preserve the ability of this form of drug delivery to qualify for an accelerated regulatory filing with the United States Food and Drug Administration (“FDA”), plus other regulators around the world.
DehydraTECH provides a potential for cost savings to the health care system by delivering anti-viral drugs more effectively through oral administration. Medication delivery through pill form instead of a shot could...
Read More>>
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company's newsroom at
About HempWire
HempWire (HW) is a dedicated information provider focused on (1) aggregating hemp-related news, (2) issuing HempNewsBreaks designed to update investors on the latest developments in the hemp market, (3) enhancing corporate news releases, (4) providing full-service distribution and social media offerings to public and private client-partners and (5) designing and implementing all-inclusive corporate communication solutions. HW is strategically positioned within the rapidly expanding hemp sector with a team of journalists working to help a growing roster of public and private companies reach a wide audience of investors, consumers and members of the media. We leverage a vast network of more than 5,000 key syndication outlets to deliver unparalleled visibility, recognition and content to the hemp industry. HempWire (HW) is where HEMP news, content and information converge.
To receive instant SMS alerts, text HEMPWIRE to 21000 (U.S. Mobile Phones Only)
For more information please visit
Please see full terms of use and disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published: /Disclaimer
Do you have a questions or are you interested in working with HW? Ask our Editor
HempWire (HW)
Denver, Colorado
303.498.7722 Office
...
HempWire is part of the InvestorBrandNetwork .
MENAFN09082024000224011066ID1108535905
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.